| http://www.w3.org/ns/prov#value | - And we think if we see consistent results, standard dosing, similar pharmacokinetics and safety profile which manufacture the same way and we see consistent responses that this could enable what we hope will be a class approval whether were the Exons, which in feasible to do clinical safety and efficacy studies, both there is a mechanism with the EMA and the FDA to get a broad class approval.
|
